• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经重复碳离子放射治疗和经动脉化疗栓塞治疗的肝细胞癌长期生存病例报告。

Long-term survivor of hepatocellular carcinoma treated with repeated carbon ion radiotherapy and transarterial chemoembolization: a case report.

机构信息

Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Maebashi, Gunma, 371-8511, Japan.

Gunma University Heavy Ion Medical Center, 3-39-22, Showa-machi, Maebashi, Gunma, 371-8511, Japan.

出版信息

Clin J Gastroenterol. 2022 Aug;15(4):771-775. doi: 10.1007/s12328-022-01642-4. Epub 2022 Jun 9.

DOI:10.1007/s12328-022-01642-4
PMID:35679000
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9334374/
Abstract

Hepatocellular carcinoma (HCC) often recurs in the liver and requires multiple rounds of treatment. Thus, less-invasive multidisciplinary approaches are essential for preserving liver function, especially in elderly patients. Here, we report a case of an 86 year-old Japanese male patient with HCC who was successfully treated with repeated carbon ion radiotherapy (C-ion RT) and transarterial chemoembolization (TACE). The patient had alcoholic liver cirrhosis with a 60 mm HCC lesion and a satellite lesion in segment 6. The patient underwent initial C-ion RT but developed primary tumor recurrence (segment 6) and a new lesion (segment 2) 24 months later. The patient received TACE for each lesion, followed by an increased dose of C-ion RT for the recurrent primary tumor. Although the primary tumor lesion was well controlled, the patient subsequently developed new lesions, and TACE was repeated. The patient died of bacterial pneumonia 88 months after the initial treatment. His general condition and liver function were well preserved, and no severe adverse events were observed throughout the course of treatment. These results suggest that a less-invasive multidisciplinary approach involving repeated C-ion RT combined with TACE enables preservation of liver function, which may contribute to long-term survival in elderly patients with HCC.

摘要

肝细胞癌 (HCC) 常在肝脏内复发,需要多次治疗。因此,对于保留肝功能,尤其是老年患者,微创的多学科方法至关重要。在此,我们报告了一例成功接受多次碳离子放疗 (C-ion RT) 和经动脉化疗栓塞 (TACE) 治疗的 86 岁日本男性 HCC 患者。该患者患有酒精性肝硬化,有一个 60mm 的 HCC 病灶和一个 6 段的卫星病灶。该患者最初接受了 C-ion RT,但 24 个月后出现原发性肿瘤复发 (6 段) 和新病灶 (2 段)。每个病灶均接受了 TACE 治疗,随后对复发性原发性肿瘤增加了 C-ion RT 的剂量。虽然原发性肿瘤病灶得到了很好的控制,但随后患者又出现了新的病灶,再次进行了 TACE 治疗。患者在初始治疗后 88 个月因细菌性肺炎去世。他的一般状况和肝功能得到了很好的维持,在整个治疗过程中没有观察到严重的不良反应。这些结果表明,包括重复 C-ion RT 联合 TACE 的微创多学科方法可保留肝功能,有助于 HCC 老年患者的长期生存。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a184/9334374/01d24c10bdec/12328_2022_1642_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a184/9334374/a5dfc4dbf6bd/12328_2022_1642_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a184/9334374/1eb8ea1c9778/12328_2022_1642_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a184/9334374/a1154b5c8670/12328_2022_1642_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a184/9334374/5ae0c96894c6/12328_2022_1642_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a184/9334374/01d24c10bdec/12328_2022_1642_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a184/9334374/a5dfc4dbf6bd/12328_2022_1642_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a184/9334374/1eb8ea1c9778/12328_2022_1642_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a184/9334374/a1154b5c8670/12328_2022_1642_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a184/9334374/5ae0c96894c6/12328_2022_1642_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a184/9334374/01d24c10bdec/12328_2022_1642_Fig5_HTML.jpg

相似文献

1
Long-term survivor of hepatocellular carcinoma treated with repeated carbon ion radiotherapy and transarterial chemoembolization: a case report.经重复碳离子放射治疗和经动脉化疗栓塞治疗的肝细胞癌长期生存病例报告。
Clin J Gastroenterol. 2022 Aug;15(4):771-775. doi: 10.1007/s12328-022-01642-4. Epub 2022 Jun 9.
2
A comparison of carbon ion radiotherapy and transarterial chemoembolization treatment outcomes for single hepatocellular carcinoma: a propensity score matching study.碳离子放疗与经肝动脉化疗栓塞术治疗单个肝细胞癌的疗效比较:一项倾向评分匹配研究。
Radiat Oncol. 2019 Aug 2;14(1):137. doi: 10.1186/s13014-019-1347-4.
3
Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.微血管侵犯作为索拉非尼联合经肝动脉化疗栓塞治疗复发性中期肝细胞癌疗效预测因子的研究
Radiology. 2019 Jul;292(1):237-247. doi: 10.1148/radiol.2019181818. Epub 2019 May 28.
4
Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: Necessity to subclassify Barcelona Clinic Liver Cancer stage C.联合经动脉化疗栓塞和放疗作为伴宏观血管侵犯的肝细胞癌的一线治疗:巴塞罗那临床肝癌分期 C 有必要再分类。
Radiother Oncol. 2019 Dec;141:95-100. doi: 10.1016/j.radonc.2019.08.009. Epub 2019 Sep 7.
5
Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy.巨大原发性肝细胞癌:单纯经动脉化疗栓塞治疗与联合经动脉化疗栓塞-经皮微波凝固治疗的比较。
J Gastroenterol Hepatol. 2013 Mar;28(3):456-63. doi: 10.1111/jgh.12088.
6
Prognostic Survival Factors of Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.经肝动脉化疗栓塞治疗的肝细胞癌的预后生存因素。
Klin Onkol. 2020 Spring;33(3):214-219. doi: 10.14735/amko2020214.
7
Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial.经动脉化疗栓塞联合外照射放疗与索拉非尼治疗伴有宏观血管侵犯的肝细胞癌的疗效和安全性:一项随机临床试验。
JAMA Oncol. 2018 May 1;4(5):661-669. doi: 10.1001/jamaoncol.2017.5847.
8
Transarterial Chemoembolization Followed by Radiotherapy Versus Sandwich Treatment for Unresectable or Ablative Hepatocellular Carcinoma.经动脉化疗栓塞术联合放疗与三明治治疗不可切除或消融治疗的肝细胞癌。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820983799. doi: 10.1177/1533033820983799.
9
Thermal Ablation Versus Stereotactic Body Radiotherapy After Transarterial Chemoembolization for Inoperable Hepatocellular Carcinoma: A Propensity Score-Weighted Analysis.经动脉化疗栓塞术治疗后无法手术的肝细胞癌行热消融与立体定向体部放疗的疗效比较:倾向评分加权分析。
AJR Am J Roentgenol. 2021 Sep;217(3):691-698. doi: 10.2214/AJR.20.24117. Epub 2020 Sep 30.
10
Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes.放疗联合经动脉化疗栓塞治疗侵犯门静脉的肝细胞癌:长期患者结局。
Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):2004-11. doi: 10.1016/j.ijrobp.2011.03.019. Epub 2011 May 27.

本文引用的文献

1
Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: The STRSPH study.立体定向体部放疗用于既往未治疗的孤立性原发性肝细胞癌的多中心前瞻性研究:STRSPH研究
Hepatol Res. 2021 Apr;51(4):461-471. doi: 10.1111/hepr.13595. Epub 2021 Mar 1.
2
Clinical impact of Hypofractionated carbon ion radiotherapy on locally advanced hepatocellular carcinoma.局部晚期肝细胞癌分次碳离子放疗的临床影响。
Radiat Oncol. 2020 Aug 14;15(1):195. doi: 10.1186/s13014-020-01634-z.
3
A Multi-Institutional Retrospective Study of Repeated Stereotactic Body Radiation Therapy for Intrahepatic Recurrent Hepatocellular Carcinoma.
多机构回顾性研究立体定向体部放射治疗肝内复发性肝细胞癌。
Int J Radiat Oncol Biol Phys. 2020 Dec 1;108(5):1265-1275. doi: 10.1016/j.ijrobp.2020.07.034. Epub 2020 Jul 23.
4
Stereotactic Body Radiotherapy Combined with Transcatheter Arterial Chemoembolization versus Stereotactic Body Radiotherapy Alone as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis and Systematic Review.立体定向体部放射治疗联合经动脉化疗栓塞术与单纯立体定向体部放射治疗作为不可切除肝细胞癌一线治疗的比较:一项荟萃分析和系统评价
Chemotherapy. 2019;64(5-6):248-258. doi: 10.1159/000505739. Epub 2020 Apr 22.
5
Comparison of Dose Distributions When Using Carbon Ion Radiotherapy Versus Intensity-modulated Radiotherapy for Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Retrospective Analysis.碳离子放疗与调强放疗治疗合并大血管侵犯的肝细胞癌的剂量分布比较:一项回顾性分析。
Anticancer Res. 2020 Jan;40(1):459-464. doi: 10.21873/anticanres.13974.
6
Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan.日本第20次全国原发性肝癌随访调查结果报告。
Hepatol Res. 2020 Jan;50(1):15-46. doi: 10.1111/hepr.13438. Epub 2020 Jan 5.
7
A comparison of carbon ion radiotherapy and transarterial chemoembolization treatment outcomes for single hepatocellular carcinoma: a propensity score matching study.碳离子放疗与经肝动脉化疗栓塞术治疗单个肝细胞癌的疗效比较:一项倾向评分匹配研究。
Radiat Oncol. 2019 Aug 2;14(1):137. doi: 10.1186/s13014-019-1347-4.
8
A feasibility study of high-dose hypofractionated carbon ion radiation therapy using four fractions for localized hepatocellular carcinoma measuring 3 cm or larger.对于直径 3cm 或更大的局限性肝细胞癌,采用四分次大剂量分割碳离子放射治疗的可行性研究。
Radiother Oncol. 2019 Mar;132:230-235. doi: 10.1016/j.radonc.2018.10.009. Epub 2018 Oct 23.
9
Repeated SBRT for in- and out-of-field recurrences in the liver.肝内和肝外靶区复发的多次 SBRT。
Strahlenther Onkol. 2019 Mar;195(3):246-253. doi: 10.1007/s00066-018-1385-0. Epub 2018 Oct 23.
10
No Deterioration in Clinical Outcomes of Carbon Ion Radiotherapy for Sarcopenia Patients with Hepatocellular Carcinoma.肝细胞癌伴肌肉减少症患者碳离子放疗的临床结局无恶化
Anticancer Res. 2018 Jun;38(6):3579-3586. doi: 10.21873/anticanres.12631.